Features of metabolic correction in patients after percutaneous coronary intervention for acute coronary syndrome without ST elevation


  • L.S. Kholopov Odessa National Medical University,
  • N. V. Chumachenko Odessa National Medical University,
  • I. A. Sydorenko Odessa National Medical University,




Metabolic Diseases, Quercetin, Percutaneous Coronary Intervention, Myocardial Ischemia


Aim. Coronary artery disease (CAD) with concomitant metabolic syndrome (MS) leads to early disability and poor prognosis after urgent percutaneous coronary intervention (PCI) for acute coronary syndrome without elevation ST (ACS noST).

Mathods and results. With the aim of treatment effectiveness improvement, 64 patients were treated (M : F = 55 : 9, mean age 66.9±12.4 years) in two regimens – standard (group I) and with metabolic supplement (group II). Patients in groups didn`t differ in the major clinical, anamnestic, laboratory and instrumental parameters. It was found, that in the II group (n= 33), those patients received in addition to the standard therapy quercetin, 40 mg three times daily for 12.07±1.51 months, compared with the group I (n=31), number of patients with MS` criteria decreased to 48.5% (n=16) and 77.4% (n=24), respectively. These results were obtained by reducing the waist circumflex of patients in the group II compared to the group I (p=0.034) and body mass index (p=0.048); improvement of insulin resistance (calculated by index HOMA) in group II patients in comparison to the group I (p=0.049), fasting blood glucose (p=0.024), low density lipoproteins (p=0.049) and plasma thrombin (p=0.0002). High density lipoproteins were significantly higher in group II patients compared to the group I (p=0.049).

Conclusions: Long-term quercetin use in addition to standard therapy in patients with CAD and MS after PCI on the ACS without ST leads to the improvement of the system of metabolism due to the correction of the parameters of the metabolic syndrome. 


Maksyutina, N. P., Mojbenko, A. A., Mokhort, N. A., et al. (2012) Bioflavonoidy kak organoprotektory: kvercetin, korvitin, kvertin [Bioflavonoids as organoprotektors: quercetin, korvitin, quertin]. A.A. Mojbenko (Ed.). Kyiv: Naukova dumka. [in Ukrainian].

Hlushko, L. V., Nasrallakh, A. Kh., Fedorov, S. V. (2013) [Effect of quercetin on anti-inflammatory activity of peripheral blood monocytes in women with metabolic syndrome in postmenopausal]. News of pharmacy, 4(76), 79–81. [in Ukrainian].

Karpov, Yu. A., & Buza, V. V. (2011) Kak vesti bol'nogo posle chreskozhnogo koronarnogo vmeshatel'stva? [How keep the patient after percutaneous coronary intervention?]. Rossijskij medicinskij zhurnal, 19(26), 1604–1609. [in Russian].

Kuz'menko, M. O. (2013) Systemni ta molekuliarno-henetychni mekhanizmy remodeliuvannia sertsia ta yoho eksperymentalna terapiia za dopomohoiu bioflavonoidiv (Avtoref. dis…kand. biol. nauk). [System and molecular genetic mechanisms of cardiac remodeling and its experimental therapy with bioflavonoids]. (Extended abstract of candidate’s thesis). Kyiv. [in Ukrainian].

Chumakova, G. A., Veselovskaya, N. G., & Kozarenko, A. A. (2010) Faktory riska restenozov posle revaskulyarizacii miokarda u pacientov s metabolicheskim sindromom i sakharnym diabetom 2 tipa [Factors of risk of restenosis after myocardial revascularization in patients with metabolic syndrome and type 2 diabetes]. Serdce : zhurnal dlya praktikuyushikh vrachej, 9(1), 14–27. [in Russian].

Shimanovskij, N. L., Matyushin, A. I., & Rogovskij, V. S. (2013) Perspektivy primeneniya preparatov kvercetina dlya profilaktiki i lecheniya ateroskleroza [Prospects of application quercetin drug for prevention and treatment of atherosclerosis]. Medical Nature, 2(14), 66–69. [in USA].

Kuzmenko, M. A., Pavlyuchenko, V. B., Tumanovskaya, L. V., Dosenko, V. E., & Mojbenko, A. A. (2013) E′ksperimental'naya terapiya remodelirovaniya serdca s pomosch'yu preparatov kvercetina [Experimental therapy of cardiac remodeling with quercetin-containing drugs]. Patologicheskaya fiziologiya i e′ksperimental'naya terapiya, 2,17–22. [in Russian].

Galleano, M., Calabro, V., Prince, P., Litterio, M., Piotrkowski, B., Vazquez-Prieto, M., et al. (2012) Flavonoids and metabolic syndrome. Annals of the New York Academy of Sciences., 1259(1), 87–94. doi: 10.1111/j.1749-6632.2012.06511.x.

Kim, J., Mun, H., Lee, B., Yoon, S., Choi, E., Min, P., et al. (2010) Impact of Metabolic Syndrome and Its Individual Components on the Presence and Severity of Angiographic Coronary Artery Disease. Yonsei Medical Journal., 51(5), 676–682. doi: 10.3349/ymj.2010.51.5.676.

Mosawy, S. (2015) Effect of the flavonol quercetin on human platelet function: a review. Food and Public Health., 5(1), 1–9. doi: 10.5923/j.fph.20150501.01.

How to Cite

Kholopov L, Chumachenko NV, Sydorenko IA. Features of metabolic correction in patients after percutaneous coronary intervention for acute coronary syndrome without ST elevation. Zaporozhye Medical Journal [Internet]. 2016May23 [cited 2024Jul.21];18(2). Available from: http://zmj.zsmu.edu.ua/article/view/69164



Original research